These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 25726752)
21. Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy. Arias L; Caminal JM; Badia MB; Rubio MJ; Catala J; Pujol O Retina; 2010; 30(10):1601-8. PubMed ID: 21060271 [TBL] [Abstract][Full Text] [Related]
22. Effects of repeated intravitreal bevacizumab injections on the inner retinal function in neovascular age-related macular degeneration. Kim HD; Kim SH; Cho IH; Moon CH; Ohn YH; Park TK Acta Ophthalmol; 2013 Mar; 91(2):e154-6. PubMed ID: 22989051 [No Abstract] [Full Text] [Related]
23. Profile of intraocular immune mediators in patients with age-related macular degeneration and the effect of intravitreal bevacizumab injection. Agawa T; Usui Y; Wakabayashi Y; Okunuki Y; Juan M; Umazume K; Kezuka T; Takeuchi M; Yamauchi Y; Goto H Retina; 2014 Sep; 34(9):1811-8. PubMed ID: 24801651 [TBL] [Abstract][Full Text] [Related]
24. Ultrasound assessment of ocular vascular effects of repeated intravitreal injections of ranibizumab for wet age-related macular degeneration. Bonnin P; Pournaras JA; Makowiecka K; Krivosic V; Kedra AW; Le Gargasson JF; Gaudric A; Levy BI; Cohen YS; Tadayoni R; Massin P Acta Ophthalmol; 2014 Aug; 92(5):e382-7. PubMed ID: 25043792 [TBL] [Abstract][Full Text] [Related]
27. Reflux of drug during intra-vitreal anti-VEGF therapies. Usman Saeed M; Batra R; Qureshi F; Clark D Semin Ophthalmol; 2011 Nov; 26(6):357-60. PubMed ID: 22044333 [TBL] [Abstract][Full Text] [Related]
29. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure. Kim YJ; Sung KR; Lee KS; Joe SG; Lee JY; Kim JG; Yoon YH Am J Ophthalmol; 2014 Jun; 157(6):1266-1271.e1. PubMed ID: 24561173 [TBL] [Abstract][Full Text] [Related]
30. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration]. Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687 [TBL] [Abstract][Full Text] [Related]
31. Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration. Hosseini H; Lotfi M; Esfahani MH; Nassiri N; Khalili MR; Razeghinejad MR; Nouri-Mahdavi K Retina; 2012 May; 32(5):967-71. PubMed ID: 22146127 [TBL] [Abstract][Full Text] [Related]
32. Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration. Vaze A; Fraser-Bell S; Gillies M Retina; 2014 Sep; 34(9):1774-8. PubMed ID: 24837049 [TBL] [Abstract][Full Text] [Related]
33. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage. Treumer F; Roider J; Hillenkamp J Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095 [TBL] [Abstract][Full Text] [Related]
34. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics. Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560 [TBL] [Abstract][Full Text] [Related]
36. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity. Saito M; Iida T; Kano M Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886 [TBL] [Abstract][Full Text] [Related]
37. Growth of type 1 neovascularization following cessation of anti-vascular endothelial growth factor therapy as a possible explanation for treatment resistance. Shah VP; Freund KB JAMA Ophthalmol; 2013 Jul; 131(7):967-9. PubMed ID: 23846209 [No Abstract] [Full Text] [Related]
39. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. Gomi F; Sawa M; Tsujikawa M; Nishida K Retina; 2012 Oct; 32(9):1804-10. PubMed ID: 22718152 [TBL] [Abstract][Full Text] [Related]
40. Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity. Axer-Siegel R; Bor E; Bourla DH; Weinberger D; Mimouni K Retina; 2012 Oct; 32(9):1811-20. PubMed ID: 22825407 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]